论文部分内容阅读
目的观察参麦注射液联合环磷腺苷葡胺注射液治疗冠心病心力衰竭的效果。方法按照入院顺序抽取我院自2015年1月至2017年1月收治的冠心病心力衰竭患者90例,分为联合组(n=45)和常规组(n=45)。常规组进行常规治疗,联合组在常规组的基础上进行参麦注射液联合环磷腺苷葡胺注射液治疗。对比两组的治疗效果以及心功能(LVEF、LVEDD、LVESD)。结果与常规组的治疗效果比较,联合组的较高;与常规组的心功能比较,联合组的较优,差异有统计学意义(P<0.05)。结论参麦注射液联合环磷腺苷葡胺注射液治疗冠心病心力衰竭,患者的临床症状以及心功能得到了显著的改善,值得借鉴和推广。
Objective To observe the effect of Shenmai injection combined with cyclophosphamide meglumine on heart failure in patients with coronary heart disease. Methods Totally 90 patients with heart failure of CHD treated in our hospital from January 2015 to January 2017 were divided into the combined group (n = 45) and the conventional group (n = 45). Routine treatment of conventional group, the joint group on the basis of the conventional group of Shenmai injection combined with cyclophosphamide meglumine injection treatment. The therapeutic effects and cardiac function (LVEF, LVEDD, LVESD) were compared between the two groups. Results Compared with the conventional treatment group, the combination group had a higher level. Compared with the conventional group, the combined group was superior and the difference was statistically significant (P <0.05). Conclusion Shenmai injection combined with cyclophosphamide meglumine injection in the treatment of heart failure of coronary heart disease, the clinical symptoms and cardiac function of patients have been significantly improved, it is worth learning and promotion.